Orphan designation was granted by the FDA to Rezolute’s (RZLT) ersodetug for the treatment of hypoglycemia due to tumor-associated hyperinsulinism, according to a post to the agency’s website.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.